Market Trends of Alpha-glucosidase Inhibitors Industry
Rising diabetes prevalence globally
The diabetes population globally is expected to rise by 1.9% over the forecast period.
According to International Diabetes Federation, the adult diabetes population was approximately 537 million, which will increase by 643 million in 2030. Obesity is considered one of the major factors contributing to the disease, primarily Type 2 diabetes. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage.
Type 2 diabetes is increasingly prevalent and associated with an increased cardiovascular and renal disease risk. Alpha-glucosidase inhibitors may also be used in patients with impaired glucose tolerance and delay the occurrence of type 2 diabetes mellitus in these patients. They are particularly useful for patients at risk of hypoglycemia or lactic acidosis and are unsuitable candidates for other antidiabetic drugs such as sulfonylureas and metformin. Alpha-glucosidase inhibitors are FDA approved for the treatment of type 2 diabetes mellitus.
WHO launched the Global Diabetes Compact, a global initiative to improve diabetes prevention and care, focusing on supporting low and middle-income countries. The Compact is bringing together national governments, UN organizations, nongovernmental organizations, private sector entities, academic institutions, philanthropic foundations, people living with diabetes, and international donors. The Compact aims to work on a shared vision of reducing the risk of diabetes and ensuring that all people diagnosed with diabetes can access equitable, comprehensive, affordable, and quality treatment and care.
Therefore, the studied market is anticipated to grow over the analysis period due to increased prevalence and the above factors.
Middle East and Africa is expected to register the highest CAGR in Alpha-glucosidase Inhibitors Market over the forecast period
Over the forecast period, the Middle East and Africa region is expected to witness a CAGR of more than 3.6%.
Acarbose (Precose), Voglibose, and miglitol (Glyset) are medications in Alpha-glucosidase inhibitors class of drugs. These drugs help keep the amount of glucose in the blood from rising too fast after meals. Alpha-glucosidase inhibitors help lower postprandial diabetes. These medications reduce glycosylated hemoglobin levels and lower the postprandial insulin concentration. Regulation of post-meal hyperglycemia is vital as it is associated with the development of complications and also increases the risk of heart problems.
The Government is working on plans and policies to control the outcomes of diabetes. For instance, in July 2022, Saudi Government announced that Saudi Arabia saw a growing demand for quality healthcare services spurred by changes. It includes an increasing aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The Government and private sector are involved in working on healthcare entities, certifications, and regulations. The Government is taking steps to include 100% of Saudi citizens covered by insurance. They are also working towards ensuring affordability, access, quality digital healthcare, and primary care with cost-effectiveness.
The market is expected to grow during the forecast period due to the factors above.
